Fisetin to Improve Vascular Function in Older Adults

Launched by UNIVERSITY OF COLORADO, BOULDER · Nov 10, 2023

Keywords

ClinConnect Summary

This clinical trial is exploring whether a natural compound called fisetin can help improve blood vessel function and reduce stiffness in the arteries of older adults. Researchers want to see if fisetin can make a difference in how well blood vessels work as we age by looking at factors like stress in our cells and the aging process itself. They are also checking how safe fisetin is and if people can stick to the treatment plan.

To participate, you need to be at least 65 years old, and if you're a woman, you must be postmenopausal. You should have a stable weight and not have serious ongoing health issues. During the study, you’ll receive either the fisetin treatment or a placebo (a harmless substance) and will be monitored closely. The trial is currently looking for volunteers, and if you are interested, it’s important to discuss this with your doctor to see if you meet all the eligibility requirements.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • Age 65 years or older
• • Women must be postmenopausal
• • Body mass index (BMI) \<40 kg/m2
• • Willing to accept random assignment
• • Weight stable in the prior 2 months (\<2 kg weight change) and willing to remain weight stable throughout the study
• • Ability to understand study procedures and to comply with them for the entire length of the study
• • No blood donation within 8 weeks prior to baseline testing; willingness to abstain from blood donation during the study and for 8 weeks after study completion
• • Absence of established, serious, unstable, chronic clinical disease (e.g., unstable CVD) as determined by study physician of record based on subject medical history, physical examination, resting ECG and standard clinical blood chemistries
• Exclusion Criteria:
• • Inability to refrain from alcohol for 24 hours prior to outcome assessment
• • Individuals taking fisetin, quercetin, luteolin, Dasatinib, piperlongumine or Navitoclax (supplements or drugs with established senolytic effects) within 6 months prior to baseline testing; should new research reveal other dietary supplements or drugs with potential senolytic effects, their use will be evaluated, and their use may lead to exclusion of the subject by the PI
• • New use of regular cardiovascular-acting medication which, in the opinion of the PI, affects the outcomes of the study within 3 months prior to starting baseline testing as reported during medication review during screening (these individuals could be enrolled after 3 months of regular use)
• • Chronic use of a dietary supplement which, in the opinion of the PI, affects the outcomes of the study, within 1 month prior to starting baseline testing as reported during medication review during screening (these individuals could be enrolled after 1 month of regular use)
• • Active malignancy (including myeloma) or malignancy that was active within 5 years prior to baseline testing
• • Inability or unwillingness of individual to give written informed consent
• • Current or past participation within 3 months in another clinical trial that, in the opinion of the PI, would affect the outcomes of the study
• • Known hypersensitivity or allergy to fisetin
• • Blood donation within 2 months prior to baseline testing
• • Resting blood pressure \>160 mmHg systolic or \>110 mmHg diastolic
• • Regular vigorous aerobic/endurance exercise